Clinical Trial Update: A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated 10 mg and 30 mg doses of CVL-231 (emraclidine) in participants with schizophrenia; the study is completed and results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• CVL-231 (Emraclidine) (emraclidine)

Snippet

Sponsor: AbbVie | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2025-09-17